ArticleFrontiers in pediatrics2024

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.

Bosco Paes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.